-
1
-
-
0030056093
-
Follow-up of bone lesions in an experimental multiple myeloma mouse model: Description of an in vivo technique using radiography dedicated for mammography
-
8664113 Jun.
-
Vanderkerken K, Goes E, De Raeve H, Radl J, Van Camp B. Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography. Br J Cancer. 1996 Jun; 73(12):1463-5. PMID: 8664113
-
(1996)
Br J Cancer
, vol.73
, Issue.12
, pp. 1463-1465
-
-
Vanderkerken, K.1
Goes, E.2
De Raeve, H.3
Radl, J.4
Van Camp, B.5
-
2
-
-
0030977162
-
A murine model of human myeloma bone disease
-
9177864 Jun.
-
Garrett IR, Dallas S, Radl J, Mundy GR. A murine model of human myeloma bone disease. Bone. 1997 Jun; 20(6):515-20. PMID: 9177864
-
(1997)
Bone
, vol.20
, Issue.6
, pp. 515-520
-
-
Garrett, I.R.1
Dallas, S.2
Radl, J.3
Mundy, G.R.4
-
3
-
-
84871436882
-
A novel mouse model for multiple myeloma (MOPC315. BM) that allows noninvasive spatiotemporal detection of osteolytic disease
-
23284805
-
Hofgaard PO, Jodal HC, Bommert K, Huard B, Caers J, Carlsen H, et al. A novel mouse model for multiple myeloma (MOPC315. BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PloS one. 2012;7(12):e51892. doi: 10.1371/journal.pone.0051892 PMID: 23284805
-
(2012)
PloS One
, vol.7
, Issue.12
, pp. e51892
-
-
Hofgaard, P.O.1
Jodal, H.C.2
Bommert, K.3
Huard, B.4
Caers, J.5
Carlsen, H.6
-
4
-
-
0027534880
-
Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease
-
8443818 Mar. 15
-
Huang YW, Richardson JA, Tong AW, Zhang BQ, Stone MJ, Vitetta ES. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res. 1993 Mar. 15; 53(6):1392-6. PMID: 8443818
-
(1993)
Cancer Res.
, vol.53
, Issue.6
, pp. 1392-1396
-
-
Huang, Y.W.1
Richardson, J.A.2
Tong, A.W.3
Zhang, B.Q.4
Stone, M.J.5
Vitetta, E.S.6
-
5
-
-
22844450849
-
The SCID-hu myeloma model
-
15968103
-
Epstein J, Yaccoby S. The SCID-hu myeloma model. Methods Mol Med. 2005;113:183-90. PMID: 15968103
-
(2005)
Methods Mol Med.
, vol.113
, pp. 183-190
-
-
Epstein, J.1
Yaccoby, S.2
-
6
-
-
38549131395
-
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
-
18242516 Feb.
-
Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer cell. 2008 Feb; 13(2):167-80. doi: 10.1016/j.ccr.2008.01.007 PMID: 18242516
-
(2008)
Cancer Cell
, vol.13
, Issue.2
, pp. 167-180
-
-
Chesi, M.1
Robbiani, D.F.2
Sebag, M.3
Chng, W.J.4
Affer, M.5
Tiedemann, R.6
-
7
-
-
34047136169
-
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis
-
17418411 Apr.
-
Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco DE, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer cell. 2007 Apr; 11(4):349-60. PMID: 17418411
-
(2007)
Cancer Cell
, vol.11
, Issue.4
, pp. 349-360
-
-
Carrasco, D.R.1
Sukhdeo, K.2
Protopopova, M.3
Sinha, R.4
Enos, M.5
Carrasco, D.E.6
-
8
-
-
84866156501
-
Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus
-
22516053 Oct.
-
Bartee E, Chan WM, Moreb JS, Cogle CR, McFadden G. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2012 Oct; 18(10):1540-51. doi: 10.1016/j.bbmt.2012.04.004 PMID: 22516053
-
(2012)
Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation
, vol.18
, Issue.10
, pp. 1540-1551
-
-
Bartee, E.1
Chan, W.M.2
Moreb, J.S.3
Cogle, C.R.4
McFadden, G.5
-
9
-
-
84863908333
-
Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model
-
22271890 Jul
-
Swift BE, Williams BA, Kosaka Y, Wang XH, Medin JA, Viswanathan S, et al. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica. 2012 Jul; 97(7):1020-8. doi: 10.3324/haematol. 2011.054254 PMID: 22271890
-
(2012)
Haematologica
, vol.97
, Issue.7
, pp. 1020-1028
-
-
Swift, B.E.1
Williams, B.A.2
Kosaka, Y.3
Wang, X.H.4
Medin, J.A.5
Viswanathan, S.6
-
10
-
-
84872345792
-
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
-
23169779 Jan 10
-
Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood. 2013 Jan 10; 121(2):318-28. doi: 10.1182/blood-2012-06-436220 PMID: 23169779
-
(2013)
Blood
, vol.121
, Issue.2
, pp. 318-328
-
-
Chaidos, A.1
Barnes, C.P.2
Cowan, G.3
May, P.C.4
Melo, V.5
Hatjiharissi, E.6
-
11
-
-
84892380481
-
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rgamma (null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies
-
24223204
-
Schueler J, Wider D, Klingner K, Siegers GM, May AM, Wasch R, et al. Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rgamma (null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. PloS one. 2013;8(11):e79939. doi: 10.1371/journal.pone.0079939 PMID: 24223204
-
(2013)
PloS One
, vol.8
, Issue.11
, pp. e79939
-
-
Schueler, J.1
Wider, D.2
Klingner, K.3
Siegers, G.M.4
May, A.M.5
Wasch, R.6
-
12
-
-
84874336478
-
Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment
-
23437401
-
Fryer RA, Graham TJ, Smith EM, Walker-Samuel S, Morgan GJ, Robinson SP, et al. Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment. PloS one. 2013;8(2):e57641. doi: 10.1371/journal.pone.0057641 PMID: 23437401
-
(2013)
PloS One
, vol.8
, Issue.2
, pp. e57641
-
-
Fryer, R.A.1
Graham, T.J.2
Smith, E.M.3
Walker-Samuel, S.4
Morgan, G.J.5
Robinson, S.P.6
-
13
-
-
84857013000
-
Therapeutic potential of SH2 domaincontaining inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer
-
22033675
-
Fuhler GM, Brooks R, Toms B, Iyer S, Gengo EA, Park MY, et al. Therapeutic potential of SH2 domaincontaining inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Molecular medicine. 2012;18:65-75. doi: 10.2119/molmed.2011.00178 PMID: 22033675
-
(2012)
Molecular Medicine
, vol.18
, pp. 65-75
-
-
Fuhler, G.M.1
Brooks, R.2
Toms, B.3
Iyer, S.4
Gengo, E.A.5
Park, M.Y.6
-
14
-
-
84877087137
-
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma
-
23344265 Apr. 15
-
Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013 Apr. 15; 19(8):2048-60. doi: 10.1158/1078-0432. CCR-12-2422 PMID: 23344265
-
(2013)
Clin Cancer Res.
, vol.19
, Issue.8
, pp. 2048-2060
-
-
Carpenter, R.O.1
Evbuomwan, M.O.2
Pittaluga, S.3
Rose, J.J.4
Raffeld, M.5
Yang, S.6
-
15
-
-
84875050694
-
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: Induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization
-
23384035 Apr.
-
Udi J, Schuler J, Wider D, Ihorst G, Catusse J, Waldschmidt J, et al. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. Br J Haematol. 2013 Apr; 161(1):104-16. doi: 10.1111/bjh.12226 PMID: 23384035
-
(2013)
Br J Haematol.
, vol.161
, Issue.1
, pp. 104-116
-
-
Udi, J.1
Schuler, J.2
Wider, D.3
Ihorst, G.4
Catusse, J.5
Waldschmidt, J.6
-
16
-
-
10744225890
-
Establishment of a new model of human multiple myeloma using NOD/SCID/gammac (null) (NOG) mice
-
14684154 Jan 9
-
Miyakawa Y, Ohnishi Y, Tomisawa M, Monnai M, Kohmura K, Ueyama Y, et al. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac (null) (NOG) mice. Biochem Biophys Res Commun. 2004 Jan 9; 313(2):258-62. PMID: 14684154
-
(2004)
Biochem Biophys Res Commun
, vol.313
, Issue.2
, pp. 258-262
-
-
Miyakawa, Y.1
Ohnishi, Y.2
Tomisawa, M.3
Monnai, M.4
Kohmura, K.5
Ueyama, Y.6
-
17
-
-
84873566871
-
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and boneanabolic activity in addition to anti-myeloma effects
-
22763387 Feb.
-
Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and boneanabolic activity in addition to anti-myeloma effects. Leukemia. 2013 Feb; 27(2):430-40. doi: 10.1038/leu.2012.183 PMID: 22763387
-
(2013)
Leukemia
, vol.27
, Issue.2
, pp. 430-440
-
-
Hurchla, M.A.1
Garcia-Gomez, A.2
Hornick, M.C.3
Ocio, E.M.4
Li, A.5
Blanco, J.F.6
-
18
-
-
84872866350
-
Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee
-
23197339 Jan.
-
Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013 Jan; 28(1):2-17. doi: 10.1002/jbmr.1805 PMID: 23197339
-
(2013)
J Bone Miner Res.
, vol.28
, Issue.1
, pp. 2-17
-
-
Dempster, D.W.1
Compston, J.E.2
Drezner, M.K.3
Glorieux, F.H.4
Kanis, J.A.5
Malluche, H.6
-
19
-
-
0242308942
-
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival
-
12619933 Mar
-
Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res. 2003 Mar; 18(3):482-92. PMID: 12619933
-
(2003)
J Bone Miner Res.
, vol.18
, Issue.3
, pp. 482-492
-
-
Croucher, P.I.1
De Hendrik, R.2
Perry, M.J.3
Hijzen, A.4
Shipman, C.M.5
Lippitt, J.6
-
20
-
-
0033105769
-
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
-
10029599 Mar. 1
-
Dallas SL, Garrett IR, Oyajobi BO, Dallas MR, Boyce BF, Bauss F, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood. 1999 Mar. 1; 93(5):1697-706. PMID: 10029599
-
(1999)
Blood
, vol.93
, Issue.5
, pp. 1697-1706
-
-
Dallas, S.L.1
Garrett, I.R.2
Oyajobi, B.O.3
Dallas, M.R.4
Boyce, B.F.5
Bauss, F.6
-
21
-
-
0035052888
-
Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma
-
11301184 Apr.
-
Cruz JC, Alsina M, Craig F, Yoneda T, Anderson JL, Dallas M, et al. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol. 2001 Apr; 29(4):441-7. PMID: 11301184
-
(2001)
Exp Hematol.
, vol.29
, Issue.4
, pp. 441-447
-
-
Cruz, J.C.1
Alsina, M.2
Craig, F.3
Yoneda, T.4
Anderson, J.L.5
Dallas, M.6
-
22
-
-
84884200814
-
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma
-
24066119
-
Hu B, Chen Y, Usmani SZ, Ye S, Qiang W, Papanikolaou X, et al. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PloS one. 2013;8(9):e74191. doi: 10.1371/journal.pone.0074191 PMID: 24066119
-
(2013)
PloS One
, vol.8
, Issue.9
, pp. e74191
-
-
Hu, B.1
Chen, Y.2
Usmani, S.Z.3
Ye, S.4
Qiang, W.5
Papanikolaou, X.6
-
23
-
-
84863229246
-
Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma
-
22234692 Mar. 8
-
Koduru S, Wong E, Strowig T, Sundaram R, Zhang L, Strout MP, et al. Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma. Blood. 2012 Mar. 8; 119(10):2302-9. doi: 10.1182/blood-2011-08-376236 PMID: 22234692
-
(2012)
Blood
, vol.119
, Issue.10
, pp. 2302-2309
-
-
Koduru, S.1
Wong, E.2
Strowig, T.3
Sundaram, R.4
Zhang, L.5
Strout, M.P.6
-
24
-
-
0032930729
-
Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice
-
9933480 Feb.
-
Hjorth-Hansen H, Seifert MF, Borset M, Aarset H, Ostlie A, Sundan A, et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res. 1999 Feb; 14(2):256-63. PMID: 9933480
-
(1999)
J Bone Miner Res.
, vol.14
, Issue.2
, pp. 256-263
-
-
Hjorth-Hansen, H.1
Seifert, M.F.2
Borset, M.3
Aarset, H.4
Ostlie, A.5
Sundan, A.6
-
26
-
-
0026558465
-
Myeloma affects both the growth and function of human osteoblast-like cells
-
Jan.
-
Evans CE, Ward C, Rathour L, Galasko CB. Myeloma affects both the growth and function of human osteoblast-like cells. Clinical & experimental metastasis. 1992 Jan; 10(1):33-8.
-
(1992)
Clinical & Experimental Metastasis
, vol.10
, Issue.1
, pp. 33-38
-
-
Evans, C.E.1
Ward, C.2
Rathour, L.3
Galasko, C.B.4
-
27
-
-
27644473781
-
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
-
16030194 Nov. 1
-
Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005 Nov. 1; 106(9):3160-5. PMID: 16030194
-
(2005)
Blood
, vol.106
, Issue.9
, pp. 3160-3165
-
-
Oshima, T.1
Abe, M.2
Asano, J.3
Hara, T.4
Kitazoe, K.5
Sekimoto, E.6
-
28
-
-
33947605189
-
HGF inhibits BMP-induced osteoblastogenesis: Possible implications for the bone disease of multiple myeloma
-
17138824 Apr. 1
-
Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood. 2007 Apr. 1; 109(7):3024-30. PMID: 17138824
-
(2007)
Blood
, vol.109
, Issue.7
, pp. 3024-3030
-
-
Standal, T.1
Abildgaard, N.2
Fagerli, U.M.3
Stordal, B.4
Hjertner, O.5
Borset, M.6
-
29
-
-
23744498205
-
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
-
15933061 Oct. 1
-
Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005 Oct. 1; 106(7):2472-83. PMID: 15933061
-
(2005)
Blood
, vol.106
, Issue.7
, pp. 2472-2483
-
-
Giuliani, N.1
Colla, S.2
Morandi, F.3
Lazzaretti, M.4
Sala, R.5
Bonomini, S.6
|